Hansoh Pharmaceutical Group (3692) Stock Overview
An investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 3692 from our risk checks.
3692 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hansoh Pharmaceutical Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$42.52 |
| 52 Week High | HK$42.78 |
| 52 Week Low | HK$15.96 |
| Beta | 0.61 |
| 1 Month Change | 13.39% |
| 3 Month Change | 20.80% |
| 1 Year Change | 128.60% |
| 3 Year Change | 186.91% |
| 5 Year Change | 22.36% |
| Change since IPO | 70.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3692 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 5.8% | 1.9% | -1.8% |
| 1Y | 128.6% | 65.9% | 27.2% |
Return vs Industry: 3692 exceeded the Hong Kong Pharmaceuticals industry which returned 66.6% over the past year.
Return vs Market: 3692 exceeded the Hong Kong Market which returned 27% over the past year.
Price Volatility
| 3692 volatility | |
|---|---|
| 3692 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.4% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 3692 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 3692's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 9,313 | Huijuan Zhong | www.hspharm.com |
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
Hansoh Pharmaceutical Group Company Limited Fundamentals Summary
| 3692 fundamental statistics | |
|---|---|
| Market cap | HK$257.41b |
| Earnings (TTM) | HK$5.27b |
| Revenue (TTM) | HK$14.53b |
Is 3692 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3692 income statement (TTM) | |
|---|---|
| Revenue | CN¥13.19b |
| Cost of Revenue | CN¥1.21b |
| Gross Profit | CN¥11.98b |
| Other Expenses | CN¥7.20b |
| Earnings | CN¥4.78b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 90.84% |
| Net Profit Margin | 36.25% |
| Debt/Equity Ratio | 0.1% |
How did 3692 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 04:56 |
| End of Day Share Price | 2025/12/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansoh Pharmaceutical Group Company Limited is covered by 39 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Ziyu He | China International Capital Corporation Limited |
| Jin Zhang | China International Capital Corporation Limited |